HERTI 150MG

Herti 150mg Injection contains Trastuzumab as its active constituent and is indicated for the treatment of HER2-positive breast cancer. In patients with HER2-positive status, breast cancer cells abundantly express HER2 proteins, which act as signals stimulating the rapid growth and development of cancerous tumors. This medication is also utilized to treat metastatic gastric cancer that exhibits elevated levels of HER2 proteins.

HER2-positive breast cancers are known for their aggressive nature. The targeted therapy provided by Herti 150mg Injection functions by selectively targeting these specific proteins responsible for the growth, development, and spread of the cancer. Patients who are able to become pregnant should use effective birth control during the entire treatment period and for at least seven months following the final dose.

Herti 150mg Injection is not recommended for patients under 18 years of age, or for those with severe breathing problems or who require oxygen therapy. It is essential to inform your physician if you have any pre-existing heart problems, experience breathlessness, or have undergone any other cancer treatment in the past. Furthermore, ensure you provide your physician with a complete list of all medications you are currently taking, including supplements and herbal medicines, before initiating treatment with this medication.